Health & Biotech CardieX gets hearts racing as MST Access reaffirms value at 5x current share price June 3, 2022 Special Report: CardieX has gots hearts racing after equities research shop MST Access placed a $1.50 valuation on the Australian… ASX Health Stocks: Alterity is set to launch Phase 2 clinical trial on Multiple System Atrophy June 2, 2022 ASX biotech Alterity is s set to launch a Phase 2 clinical trial of its lead drug, ATH43, a drug… EZZ taps into strong consumer demand for ethically, locally made personal care products June 2, 2022 Special Report: EZZ is focusing on an uptick in consumer demand for locally produced ethical beauty and personal care products. Here’s how Immutep and other immunotherapy biotechs have changed cancer treatment June 2, 2022 Immunotherapy is becoming the new gold standard in treating certain cancers Stockhead talks to Immutep CEO Mark Voigt about Immutep's… ASX Health Stocks: Mesoblast’s Q3 revenues, Osprey restructures business to reduce debt June 1, 2022 ASX biotech Mesoblast reported that revenues in the quarter have increased by 5% on the same quarter last year, to… Medlab wants to get right up COVID’s nose, as nasal vaccine program gathers steam June 1, 2022 Special Report: Medlab is changing the way medicines are delivered for better patient outcomes with promising early results from its… Significant milestone in Dimerix’s Phase 3 trial on kidney disease, with first patient recruited May 31, 2022 Special Report: The ACTION3 Phase 3 clinical trial conducted by Dimerix will study the effects of its lead drug, DMX-200,… ASX Health Stocks: Anteris implants its novel aortic valve DurAVR into 8 more patients May 31, 2022 ASX biotech Anteris said that eight more patients were successfully treated last week, as part of its ongoing first-in-human DurAVR… ASX Health Stocks: Invion demonstrates efficacy, Biotron gets feedback from the FDA May 30, 2022 Invion demonstrates high efficacy of INV043 when used as a combined therapy Biotron gets positive feedback from US FDA Biome… PharmAust’s subsidiary Epichem appoints new GM as it sets eyes on new commercial opportunities May 30, 2022 Special Report: The appointment of former Novartis exec Fiona Milner will provide PharmAust’s subsidiary Epichem the leadership it needs to… Next» « Previous